Vestal Point Capital LP Invests $2.02 Million in Bausch Health Companies Inc. (NYSE:BHC)

Vestal Point Capital LP acquired a new stake in Bausch Health Companies Inc. (NYSE:BHC - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 250,000 shares of the company's stock, valued at approximately $2,015,000. Vestal Point Capital LP owned about 0.07% of Bausch Health Companies as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Mountain Hill Investment Partners Corp. bought a new stake in shares of Bausch Health Companies during the fourth quarter valued at approximately $56,000. Bank of Nova Scotia acquired a new position in shares of Bausch Health Companies during the fourth quarter valued at $83,000. One68 Global Capital LLC bought a new position in Bausch Health Companies in the fourth quarter valued at about $90,000. Balyasny Asset Management L.P. bought a new stake in Bausch Health Companies during the 4th quarter worth about $97,000. Finally, Alpine Global Management LLC bought a new stake in Bausch Health Companies during the 4th quarter worth about $114,000. Institutional investors and hedge funds own 78.65% of the company's stock.

Bausch Health Companies Price Performance

BHC stock traded up $0.02 during trading hours on Thursday, reaching $4.50. 1,047,036 shares of the stock were exchanged, compared to its average volume of 2,583,284. The firm's 50-day moving average is $5.41 and its 200-day moving average is $6.89. Bausch Health Companies Inc. has a 12 month low of $3.96 and a 12 month high of $9.85. The company has a market cap of $1.63 billion, a price-to-earnings ratio of -37.50, a PEG ratio of 0.37 and a beta of 0.34.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The firm had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.51 billion. As a group, equities research analysts forecast that Bausch Health Companies Inc. will post 4.41 earnings per share for the current year.

Wall Street Analyst Weigh In

BHC has been the subject of several analyst reports. Royal Bank of Canada lifted their price target on shares of Bausch Health Companies from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research report on Friday, May 2nd. Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.00 price objective (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. Finally, Wall Street Zen lowered shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a report on Saturday, May 10th. One investment analyst has rated the stock with a sell rating and seven have assigned a hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $7.42.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.